Enveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm focused on developing small-molecule therapeutics for anxiety, depression, and addiction disorders, announces CEO Joseph Tucker, Ph.D., will present at the 6th Annual Growth Conference by Gravitas Securities Inc. on March 2, 2023 in Vancouver, British Columbia. Dr. Tucker's presentations include a Healthcare Panel at 1:40 p.m. PST and a Company Presentation at 2:00 p.m. PST. He will also hold one-on-one meetings with investors to discuss Enveric’s strategies, achievements, and future milestones.
Positive
None.
Negative
None.
Insights
Analyzing...
CEO Joseph Tucker, Ph.D., to deliver company presentation and participate in panel discussion
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that Joseph Tucker, Ph.D., Chief Executive Officer, will present at the Gravitas Securities Inc. 6th Annual Growth Conference being held Thursday, March 2, 2023, at the Fairmont Pacific Rim Hotel in Vancouver, British Columbia.
Details of the presentations are as follows:
Presentation Format:
Healthcare Panel
Date:
Thursday, March 2, 2023
Time:
1:40 p.m. PST
Location:
Fairmont Pacific Rim Hotel
Presentation Format:
Company Presentation
Date:
Thursday, March 2, 2023
Time:
2:00 p.m. PST
Location:
Sapphire Ballroom, Fairmont Pacific Rim Hotel
During the conference, Dr. Tucker will host individual one-on-one meetings with registered investors, showcasing Enveric’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.
About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Leveraging its unique discovery and development platform, The Psybrary™, Enveric has created a robust Intellectual Property portfolio of New Chemical Entities for specific mental health indications. Enveric’s lead program, the EVM201 Series, comprises next generation synthetic psilocybin analogues that are considered prodrugs of the active metabolite, psilocin. Enveric is developing the first product from the EVM201 Series – EB-373 – for the treatment of anxiety disorders. Enveric is also advancing its third generation of therapeutics, the EVM301 Series, to offer a holistic approach for treating central nervous system disorders. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, ABCanada. For more information, please visit www.enveric.com.
Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,”” expects” or “does not expect,” “proposed,” “is expected,” “budgets,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements consist of not purely historical statements, including any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to successfully spin-off its cannabinoid assets; the ability to achieve the value creation contemplated by technical developments; the impact of the novel coronavirus (COVID-19) on Enveric’s ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on Enveric’s ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; Enveric’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to Enveric’s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission (SEC), including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.